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LETTERS TO THE EDITOR 
We are pleased to receive Letters to the Editor on appropriate subjects. These letters should be submitted 
in typewritten form, double-spaced, and are not to exceed 2112 pages. When appropriate, we wi ll solicit com-
ments from the original a uthors. All Letters to the Editor are subject to editing and possible abridgment. 
ANTIBODIES TO BASAL CELLS 
To t h e Editor: 
The recent report by Nishikawa et al [1] of basal cell antibodies in 
patients with bullous pemphigoid suggested that further comment on 
t h eir incidence in patients with bullous diseases, other dermatoses and 
particulw'ly in burn patients would be of interest. 
Basal cell layer (BCL) antibodies, initially observed in burn patients 
by Thivolet and Beyvin [2], and in subsequent studies [3-5], have also 
been occasionally described by Van Joost [6] and others in patients 
with tox.icodermia, eg, to penicillin. 
In a recent survey of immunofluorescent studies of epithelial ant i-
bodies in burn patients [5], BCL antibodies were observed in 11% [22 
of 207]. This low incidence of BCL antibodies becomes perhaps of 
significance and noteworthy of further investigation when compared to 
an incidence of only 1.5% (38 of 2,500 specimens) in a survey of 1,902 
patients with bullous diseases and other dermatoses [7]. The latter of 
course is in shw'p contrast with the high incidence of complement-
fixing BCL ant ibodies of 67% (8 of 12) in bullous pemphigoid patients 
reported by Nishikawa et al [1]. 
Comparison of the incidence of BCL antibodies and that of other 
epithelial antibodies, i.e., to the basement-membrane zone and inter-
cellulw' w'ea ("pemphigus-like" antibodies), in burn patients suggests 
t h e presence of variations in the tissue- and species-specificity of these 
antibodies for vW'ious types of epithelia (substrates). 
The unavailability of sufficient data from studies to date precludes 
assigning any definitive association for a pathognomonic role of BCL 
antibodies, increased susceptibility to infection, and the insuing mor-
bidity and mortality in burn patients. We have, however, on the basis 
of accumulating data derived from immunologic studies of experimen-
tally-induced and clinically occurring burn injury, considered the role 
of epithelial antibodies in the maintenance of host resistance [4]. 
In brief, it has been hypothesized [4] that epithelial antibodies may 
block or neutralize a serum inhibitor suggested from preliminary studies 
to be present following burn injury [8]. This inhibitor, if left unchecked, 
may interfere with the activation of Factor B to its enzymatically active 
fOrIn in the alternative pathway of complement (c) activation and the 
su bsequent generation of biologically active C components, e.g., ana-
phylatoxins and chemotactic factors, vital to host defenses. 
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REPLY 
Compw'ison of the incidence of basal cell layer (BCL) antibodies in 
bW'n patients [1] and that of BCL ant ibodies in bullous pemphigoid 
(BP) patients [2] may mislead the interpretation of the significance of 
BCL antibodies in BP, because BCL antibodies in BP cannot be 
discussed separately from basement membrane zone (BMZ) ant ibodies. 
Our work [2] indicated that most of BP sera contain BCL antibodies 
visualized by complement immunofluorescence in association with 
BMZ antibodies and that BMZ antigen(s) responsible for the produc-
tion of BMZ antibodies have some antigenic continuity to basal cells. 
According to Drs. Ablin and Holder, BCL antibodies observed in burn 
patients seem to have protective role in terms of host resistance. In 
contrast, BMZ and BCL antibodies in BP have supposedly pathogenetic 
role in the production of subepidermal bulla with the help ofleukocytes 
[3], although we need evidence to confirm the exact role of them. 
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